{"id":498830,"date":"2021-05-26T08:06:06","date_gmt":"2021-05-26T12:06:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/"},"modified":"2021-05-26T08:06:06","modified_gmt":"2021-05-26T12:06:06","slug":"abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/","title":{"rendered":"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">&#8212; Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine are among several abstracts<\/h2>\n<h2 class=\"xn-hedline\">&#8212; Interim results on the real-world effectiveness of UBRELVY\u00ae (ubrogepant) for the acute treatment of migraine in combination with calcitonin gene-related peptide receptor (CGRP) monoclonal antibody (mAb) preventives, BOTOX\u00ae (onabotulinumtoxinA), or both from the Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study<\/h2>\n<h2 class=\"xn-hedline\">&#8212; Real-world data on the role of BOTOX\u00ae (onabotulinumtoxinA) in combination with CGRP mAbs for Chronic Migraine prevention<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">NORTH CHICAGO, Ill.<\/span>, <span class=\"xn-chron\">May 26, 2021<\/span> \/PRNewswire\/ &#8212; AbbVie (NYSE: ABBV) today announced data from its migraine portfolio will be presented at the 2021 American Headache Society (AHS) Annual Scientific Meeting, to be held virtually <span class=\"xn-chron\">June 3-6<\/span>. A total of 23 abstracts, including four podium presentations, will be shared from a broad range of studies across AbbVie&#8217;s migraine portfolio. <\/p>\n<p>&#8220;Migraine is an often-debilitating disease that affects millions of people in the prime of their lives, which is why the significant advancements AbbVie has made in the development of preventive and acute treatment options are so important,&#8221; said <span class=\"xn-person\">Mitchell Mathis<\/span>, M.D., vice president, neuroscience, AbbVie. &#8220;The data AbbVie is presenting at AHS span our full migraine portfolio and is a result of our ongoing commitment to drive progress for the migraine community.&#8221;<\/p>\n<p>Researchers will present data from several migraine studies, including findings on atogepant, AbbVie&#8217;s investigational preventive treatment of migraine in adults who meet criteria for episodic migraine, as well as data on UBRELVY<sup>\u00ae<\/sup> (ubrogepant) and BOTOX<sup>\u00ae<\/sup> (onabotulinumtoxinA).<\/p>\n<p>Key AbbVie abstracts and presentation details for the 2021 AHS Annual Scientific Meeting are outlined below. <\/p>\n<div>\n<table cellspacing=\"0\" cellpadding=\"0\" border=\"1\" class=\"prntblns\">\n<tr>\n<td nowrap=\"nowrap\" class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Abstract Title<\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\" \/>\u00a0<\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\"><br \/>\n                  <b>Presentation Details <\/b><br \/>\n                <\/span>\n              <\/p>\n<p class=\"prnews_p\">\u00a0<\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Characterizing Preventive Treatment Gaps in Migraine: Results from the CaMEO Study<\/span>\n              <\/p>\n<\/td>\n<td nowrap=\"nowrap\" class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Podium presentation<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">on demand<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Prevention of Migraine<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Podium presentation<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">on demand<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-world Evidence<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Podium presentation<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">on demand<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Real-World Evidence for Control of Patients with Chronic Migraine Who Received Calcitonin Gene\u2012Related Peptide Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 <\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Podium presentation<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">on demand<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Impact of Prior Monthly Headache Days on Migraine-Related Quality of Life: Results from the CaMEO Study<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Live-streamed poster presentation <br \/>Friday, June 4 <br \/>11:50 a.m. \u2013 12:00 p.m. ET<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Optimal Acute Treatment Is Associated with Productivity Gains in People with Migraine: Results from the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Live-streamed poster presentation<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Friday, June 4<\/span>\n              <\/p>\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">1:00 p.m. &#8211; 1:10 p.m. ET<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Real-World Evidence for the Safety and Efficacy of CGRP Monoclonal Antibody Therapy Added to OnabotulinumtoxinA Treatment for Migraine Prevention in Adult Patients with Chronic Migraine<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen3\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">[Late-Breaker] Poster<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Daily Atogepant for the Preventive Treatment of Migraine Increases Responder Rates for Reduction in Mean Monthly Migraine Days<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Poster<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Daily Atogepant Provides a Rapid Onset and Sustained Benefit in the Preventive Treatment of Migraine<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Poster <\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Atogepant 60 mg Once-Daily Shows Efficacy for the Preventive Treatment of Migraine: Results From a 52-Week Open-Label Extension Trial<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Poster<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Daily Dosing of Atogepant for the Preventive Treatment of Migraine Improved Patient-reported Outcome Measures of Activity Impairment Migraine-Diary, Migraine-Specific Quality of Life, and Headache Impact in a 52-week Trial<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Poster<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Ubrogepant Treatment When Pain is Mild Increases the Likelihood of Achieving Pain Freedom in Participants Who Treated Migraine Attacks of Mild and Moderate or Severe Pain<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Poster<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen4\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">A Novel Approach to Defining Success in the Acute Treatment of Migraine: Demonstrating Therapeutic Benefit at 1 Hour Post-dose in the Pooled ACHIEVE I and ACHIEVE II Trials<\/span>\n              <\/p>\n<\/td>\n<td class=\"prngen5\">\n<p class=\"prnews_p\">\n                <span class=\"prnews_span\">Poster<\/span>\n              <\/p>\n<\/td>\n<\/tr>\n<\/table><\/div>\n<p>The 2021 AHS Annual Scientific Session agenda can be found <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=1713283888&amp;u=https%3A%2F%2Famericanheadachesociety.org%2Fevents%2F63rd-annual-scientific-meeting%2F%23agenda&amp;a=here\" rel=\"nofollow noopener\">here<\/a>.<\/p>\n<p>\n        <b>About Atogepant<\/b><br \/>\n        <br \/>Atogepant is an investigational orally administered, CGRP receptor antagonist (gepant) specifically developed for the preventive treatment of migraine. CGRP and its receptors are expressed in regions of the nervous system associated with migraine pathophysiology. Studies have shown that CGRP levels are elevated during migraine attacks and selective CGRP receptor antagonists confer clinical benefit in migraine. Atogepant is currently under review by the U.S. Food and Drug Administration. AbbVie anticipates a regulatory decision in late Q3 2021.<\/p>\n<p>\n        <b>About BOTOX<\/b><br \/>\n        <sup><br \/>\n          <b>\u00ae<br \/><\/b><br \/>\n        <\/sup>BOTOX<sup>\u00ae<\/sup> was first approved by the FDA in 1989 for two rare eye muscle disorders \u2013 blepharospasm and strabismus in adults. Today, BOTOX<sup>\u00ae<\/sup> is FDA-approved for 12 therapeutic indications, including Chronic Migraine, overactive bladder, leakage of urine (incontinence) due to overactive bladder caused by a neurologic condition in adults, cervical dystonia, adult and pediatric spasticity, severe underarm sweating (axillary hyperhidrosis), and pediatric detrusor overactivity associated with a neurologic condition.<\/p>\n<p>\n        <b>BOTOX<sup>\u00ae<\/sup><\/b>\u00a0<b>(onabotulinumtoxinA) Important\u00a0Information<\/b><\/p>\n<p>\n        <b>Indications<\/b><br \/>\n        <br \/>BOTOX<sup>\u00ae<\/sup>\u00a0is a\u00a0prescription\u00a0medicine\u00a0that\u00a0is\u00a0injected\u00a0into\u00a0muscles and\u00a0used:<\/p>\n<ul type=\"disc\">\n<li>To treat overactive bladder symptoms such as a strong need to urinate with leaking or wetting accidents (urge urinary incontinence), a strong need to urinate right away (urgency), and urinating often (frequency) in adults 18 years and older when another type of medicine (anticholinergic) does not work well enough or cannot be taken <\/li>\n<li>To treat leakage of urine (incontinence) in adults 18 years and older with overactive bladder caused by a neurologic disease who still have leakage or cannot tolerate the side effects after trying an anticholinergic medication <\/li>\n<li>To treat overactive bladder due to a neurologic disease in children 5 years of age and older when another type of medicine (anticholinergic) does not work well enough or cannot be taken <\/li>\n<li>To prevent headaches in adults with chronic migraine who have 15 or more days each month with headache lasting 4 or more hours each day in people 18 years or older <\/li>\n<li>To treat increased muscle stiffness in people 2 years of age and older with spasticity <\/li>\n<li>To treat the abnormal head position and neck pain that happens with cervical dystonia (CD) in people 16 years and older <\/li>\n<li>To treat certain types of eye muscle problems (strabismus) or abnormal spasm of the eyelids (blepharospasm) in people 12 years of age and older<\/li>\n<\/ul>\n<p>BOTOX<sup>\u00ae<\/sup>\u00a0is also injected into the skin to treat the symptoms of severe underarm sweating (severe primary axillary hyperhidrosis) when medicines used on the skin (topical) do not work well enough in people 18 years and older.<\/p>\n<p>It\u00a0is not\u00a0known\u00a0whether BOTOX<sup>\u00ae<\/sup>\u00a0is\u00a0safe\u00a0and effective\u00a0to\u00a0prevent\u00a0headaches in patients\u00a0with\u00a0migraine who\u00a0have\u00a014\u00a0or\u00a0fewer headache\u00a0days each\u00a0month (episodic\u00a0migraine).<\/p>\n<p>BOTOX<sup>\u00ae<\/sup>\u00a0has not been shown to help people perform task-specific functions with their upper limbs or increase movement in joints that are permanently fixed in position by stiff muscles.\u00a0<\/p>\n<p>It\u00a0is not\u00a0known\u00a0whether BOTOX<sup>\u00ae<\/sup>\u00a0is safe\u00a0and effective\u00a0for severe sweating anywhere other than\u00a0your armpits.\u00a0 <\/p>\n<p>\n        <b>IMPORTANT SAFETY INFORMATION<\/b><br \/>\n        <br \/>\n        <b>BOTOX<\/b><br \/>\n        <sup>\u00ae<\/sup>\u00a0<b>may cause serious side effects that can be life threatening. Get medical help right away if you have any of these problems any time (hours to weeks) after injection of\u00a0BOTOX<\/b><sup>\u00ae<\/sup><b>:<\/b><\/p>\n<ul type=\"disc\">\n<li>\n          <b>Problems swallowing, speaking, or breathing, <\/b>due to weakening of associated muscles, can be severe and result in loss of life. You are at the highest risk if these problems are pre-existing before injection. Swallowing problems may last for several months <\/li>\n<li>\n          <b>Spread of toxin effects. <\/b>The effect of botulinum toxin may affect areas away from the injection site and cause serious symptoms including: loss of strength and all-over muscle weakness, double vision, blurred vision and drooping eyelids, hoarseness or change or loss of voice, trouble saying words clearly, loss of bladder control, trouble breathing, and trouble swallowing<\/li>\n<\/ul>\n<p>There has not\u00a0been\u00a0a\u00a0confirmed\u00a0serious case\u00a0of\u00a0spread\u00a0of\u00a0toxin\u00a0effect\u00a0away\u00a0from the injection site\u00a0when\u00a0BOTOX<sup>\u00ae<\/sup>\u00a0has been\u00a0used\u00a0at\u00a0the\u00a0recommended\u00a0dose\u00a0to treat\u00a0chronic\u00a0migraine,\u00a0severe underarm\u00a0sweating,\u00a0blepharospasm, or strabismus.<\/p>\n<p>BOTOX<sup>\u00ae<\/sup> may cause loss of strength or general muscle weakness, vision problems, or dizziness within hours to weeks of taking BOTOX<sup>\u00ae<\/sup>.\u00a0<b>If this happens,\u00a0do not\u00a0drive\u00a0a\u00a0car,\u00a0operate machinery,\u00a0or do other\u00a0dangerous activities.<\/b><\/p>\n<p>\n        <b>Do not receive\u00a0BOTOX<\/b><br \/>\n        <sup>\u00ae<\/sup>\u00a0<b>if\u00a0you:\u00a0<\/b>are allergic to any of the ingredients in BOTOX<sup>\u00ae <\/sup>(see <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=3628666418&amp;u=https%3A%2F%2Fmedia.allergan.com%2Factavis%2Factavis%2Fmedia%2Fallergan-pdf-documents%2Fproduct-prescribing%2F20190620_BTX-and-BTX-C-Med-Guide-v2-0MG1145.pdf&amp;a=Medication+Guide\" rel=\"nofollow noopener\">Medication Guide<\/a> for ingredients); had an allergic reaction to any other botulinum toxin product such as Myobloc<sup>\u00ae<\/sup> (rimabotulinumtoxinB), Dysport<sup>\u00ae<\/sup> (abobotulinumtoxinA), or Xeomin<sup>\u00ae<\/sup> (incobotulinumtoxinA); have a skin infection at the planned injection site.<\/p>\n<p>\n        <b>Do not receive\u00a0BOTOX<\/b><br \/>\n        <sup>\u00ae<\/sup>\u00a0<b>for the\u00a0treatment of urinary\u00a0incontinence\u00a0if you:\u00a0<\/b>have\u00a0a urinary\u00a0tract infection\u00a0(UTI) or cannot\u00a0empty\u00a0your bladder\u00a0on\u00a0your own\u00a0and\u00a0are\u00a0not\u00a0routinely\u00a0catheterizing. Due\u00a0to\u00a0the\u00a0risk of\u00a0urinary\u00a0retention\u00a0(not\u00a0being\u00a0able\u00a0to\u00a0empty\u00a0the\u00a0bladder),\u00a0only patients\u00a0who\u00a0are willing\u00a0and\u00a0able\u00a0to\u00a0initiate\u00a0catheterization\u00a0post\u00a0treatment,\u00a0if required,\u00a0should\u00a0be\u00a0considered\u00a0for treatment.<\/p>\n<p>\n        <i>Patients\u00a0treated\u00a0for\u00a0overactive\u00a0bladder:<\/i><br \/>\n        <br \/>In clinical trials, 36 of the 552 patients had to self-catheterize for urinary retention following treatment with BOTOX<sup>\u00ae<\/sup> compared to 2 of the 542 treated with placebo. The median duration of post-injection catheterization for these patients treated with BOTOX<sup>\u00ae <\/sup>100 Units (n = 36) was 63 days (minimum 1 day to maximum 214 days) as compared to a median duration of 11 days (minimum 3 days to maximum 18 days) for patients receiving placebo (n = 2). Patients with diabetes mellitus treated with BOTOX<sup>\u00ae<\/sup> were more likely to develop urinary retention than nondiabetics.\u00a0<\/p>\n<p>\n        <i>Adult Patients\u00a0treated\u00a0for overactive\u00a0bladder due\u00a0to\u00a0neurologic disease:<\/i><br \/>\n        <br \/>In clinical trials, 30.6% of patients (33\/108) who were not using clean intermittent catheterization (CIC) prior to injection, required catheterization for urinary retention following treatment with BOTOX<sup>\u00ae<\/sup> 200 Units as compared to 6.7% of patients (7\/104) treated with placebo. The median duration of post-injection catheterization for these patients treated with BOTOX<sup>\u00ae<\/sup> 200 Units (n = 33) was 289 days (minimum 1 day to maximum 530 days) as compared to a median duration of 358 days (minimum 2 days to maximum 379 days) for patients receiving placebo (n = 7). Among patients not using CIC at baseline, those with MS were more likely to require CIC post injection than those with SCI.<\/p>\n<p>\n        <b>The\u00a0dose\u00a0of BOTOX<\/b><br \/>\n        <sup>\u00ae<\/sup>\u00a0<b>is\u00a0not the\u00a0same\u00a0as,\u00a0or\u00a0comparable\u00a0to, another botulinum\u00a0toxin product.<\/b><\/p>\n<p>\n        <b>Serious\u00a0and\/or immediate allergic\u00a0reactions\u00a0have\u00a0been reported<\/b>,\u00a0including itching, rash, red itchy welts, wheezing, asthma symptoms, dizziness, or feeling faint. Get medical help right away if you experience symptoms; further injection of BOTOX<sup>\u00ae<\/sup> should be discontinued.<\/p>\n<p>\n        <b>Tell\u00a0your doctor about\u00a0all\u00a0your muscle\u00a0or\u00a0nerve\u00a0conditions<\/b>,<b>\u00a0<\/b>such as ALS or <span class=\"xn-person\">Lou Gehrig&#8217;s<\/span> disease, myasthenia gravis, or Lambert-Eaton syndrome, as you may be at increased risk of serious side effects, including difficulty swallowing and difficulty breathing from typical doses of\u00a0BOTOX<sup>\u00ae<\/sup>.<\/p>\n<p>\n        <b>Tell\u00a0your doctor if\u00a0you have\u00a0any breathing-related problems.\u00a0<\/b>Your doctor may monitor you for breathing problems during treatment with BOTOX<sup>\u00ae<\/sup> for spasticity or for detrusor overactivity associated with a neurologic condition. The risk of developing lung disease in patients with reduced lung function is increased in patients receiving BOTOX<sup>\u00ae<\/sup>.<\/p>\n<p>\n        <b>Cornea\u00a0problems\u00a0have\u00a0been reported.\u00a0<\/b>Cornea\u00a0(surface of the eye) problems have been reported in some people receiving BOTOX<sup>\u00ae<\/sup> for their blepharospasm, especially in people with certain nerve disorders. BOTOX<sup>\u00ae<\/sup> may cause the eyelids to blink less, which could lead to the surface of the eye being exposed to air more than is usual. Tell your doctor if you experience any problems with your eyes while receiving BOTOX<sup>\u00ae<\/sup>. Your doctor may treat your eyes with drops, ointments, contact lenses, or with an eye patch.<\/p>\n<p>\n        <b>Bleeding behind the\u00a0eye\u00a0has\u00a0been reported.\u00a0<\/b>Bleeding behind the eyeball has been reported in some people receiving BOTOX<sup>\u00ae<\/sup> for their strabismus. Tell your doctor if you notice any new visual problems while receiving BOTOX<sup>\u00ae<\/sup>.<\/p>\n<p>\n        <b>Bronchitis\u00a0and upper\u00a0respiratory\u00a0tract infections (common colds) have been reported. <\/b>Bronchitis was reported more frequently in adults receiving BOTOX<sup>\u00ae<\/sup> for upper limb spasticity. Upper respiratory infections were also reported more frequently in adults with prior breathing-related problems with spasticity. In pediatric patients treated with BOTOX<sup>\u00ae<\/sup> for upper limb spasticity, upper respiratory tract infections were reported more frequently. In pediatric patients treated with BOTOX<sup>\u00ae<\/sup> for lower limb spasticity, upper respiratory tract infections were not reported more frequently than placebo.<\/p>\n<p>\n        <b>Autonomic\u00a0dysreflexia\u00a0in patients\u00a0treated for overactive\u00a0bladder due\u00a0to neurologic disease. <\/b>Autonomic dysreflexia associated with intradetrusor injections of BOTOX<sup>\u00ae<\/sup> could occur in patients treated for detrusor overactivity associated with a neurologic condition and may require prompt medical therapy. In clinical trials, the incidence of autonomic dysreflexia was greater in adult patients treated with BOTOX<sup>\u00ae<\/sup> 200 Units compared with placebo (1.5% versus 0.4%, respectively).<\/p>\n<p>\n        <b>Tell\u00a0your doctor about\u00a0all\u00a0your medical\u00a0conditions,\u00a0including\u00a0if\u00a0you:\u00a0<\/b>have or have had bleeding problems; have plans to have surgery; had surgery on your face; weakness of forehead muscles; trouble raising your eyebrows; drooping eyelids; any other abnormal facial change; have symptoms of a urinary tract infection (UTI) and are being treated for urinary incontinence (symptoms of a urinary tract infection may include pain or burning with urination, frequent urination, or fever); have problems emptying your bladder on your own and are being treated for urinary incontinence; are pregnant or plan to become pregnant (it is not known if BOTOX<sup>\u00ae<\/sup> can\u00a0harm\u00a0your unborn baby); are breastfeeding\u00a0or plan\u00a0to\u00a0(it\u00a0is not\u00a0known\u00a0if\u00a0BOTOX<sup>\u00ae<\/sup>\u00a0passes\u00a0into\u00a0breast\u00a0milk).<\/p>\n<p>\n        <b>Tell\u00a0your doctor about\u00a0all\u00a0the\u00a0medicines\u00a0you take,\u00a0<\/b>including\u00a0prescription\u00a0and over-the-counter medicines,\u00a0vitamins,\u00a0and\u00a0herbal supplements.\u00a0Using\u00a0BOTOX<sup>\u00ae\u00a0<\/sup>with certain\u00a0other medicines may cause serious\u00a0side\u00a0effects.\u00a0<b>Do not start any\u00a0new medicines\u00a0until you have\u00a0told\u00a0your doctor that\u00a0you\u00a0have\u00a0received BOTOX<sup>\u00ae<\/sup><\/b>\u00a0<b>in the past.<\/b><\/p>\n<p>Tell\u00a0your doctor if\u00a0you\u00a0received\u00a0any\u00a0other botulinum\u00a0toxin\u00a0product\u00a0in\u00a0the\u00a0last 4 months; have received injections of botulinum toxin such as <i>Myobloc<sup>\u00ae<\/sup><\/i>,\u00a0<i>Dysport<sup>\u00ae<\/sup><\/i>, or <i>Xeomin<sup>\u00ae<\/sup><\/i>in\u00a0the\u00a0past (tell\u00a0your doctor exactly which\u00a0product\u00a0you\u00a0received);\u00a0have recently received an antibiotic by injection; take muscle relaxants; take an allergy or cold medicine; take a sleep medicine; take aspirin-like products or blood thinners.<\/p>\n<p>\n        <b>Other side\u00a0effects of\u00a0BOTOX<\/b><br \/>\n        <sup>\u00ae<\/sup>\u00a0<b>include: <\/b>dry mouth, discomfort or pain at the injection site, tiredness, headache, neck pain, eye problems: double vision, blurred vision, decreased eyesight, drooping eyelids, swelling of your eyelids, dry eyes; drooping eyebrows; and upper respiratory tract infection. In adults being treated for urinary incontinence, other side effects include urinary tract infection and painful urination. In children being treated for urinary incontinence, other side effects include urinary tract infection and bacteria in the urine. If you have difficulty fully emptying your bladder on your own after receiving BOTOX<sup>\u00ae<\/sup>, you may need to use disposable self-catheters to empty your bladder up to a few times each day until your bladder is able to start emptying again.<\/p>\n<p>For more\u00a0information\u00a0refer to\u00a0the\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=1552574926&amp;u=https%3A%2F%2Fmedia.allergan.com%2Factavis%2Factavis%2Fmedia%2Fallergan-pdf-documents%2Fproduct-prescribing%2F20190620_BTX-and-BTX-C-Med-Guide-v2-0MG1145.pdf&amp;a=Medication%C2%A0Guide\" rel=\"nofollow noopener\">Medication\u00a0Guide<\/a> or talk with\u00a0your doctor. <\/p>\n<p>You\u00a0are encouraged\u00a0to\u00a0report\u00a0negative\u00a0side\u00a0effects\u00a0of\u00a0prescription\u00a0drugs to\u00a0the FDA. Visit <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=1752981257&amp;u=http%3A%2F%2Fwww.fda.gov%2Fmedwatch&amp;a=www.fda.gov%2Fmedwatch\" rel=\"nofollow noopener\">www.fda.gov\/medwatch<\/a>\u00a0or call 1-800-FDA-1088.<\/p>\n<p>\n        <b>Please\u00a0see BOTOX<\/b><br \/>\n        <sup>\u00ae<\/sup>\u00a0<b>f<\/b><b>ull <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=3177585235&amp;u=https%3A%2F%2Fmedia.allergan.com%2Factavis%2Factavis%2Fmedia%2Fallergan-pdf-documents%2Fproduct-prescribing%2F20190620-BOTOX-100-and-200-Units-v3-0USPI1145-v2-0MG1145.pdf&amp;a=Product+Information\" rel=\"nofollow noopener\">Product Information<\/a>,\u00a0including Boxed\u00a0Warning\u00a0and <\/b><b><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=3628666418&amp;u=https%3A%2F%2Fmedia.allergan.com%2Factavis%2Factavis%2Fmedia%2Fallergan-pdf-documents%2Fproduct-prescribing%2F20190620_BTX-and-BTX-C-Med-Guide-v2-0MG1145.pdf&amp;a=Medication+Guide\" rel=\"nofollow noopener\">Medication Guide<\/a><\/b><b>.<\/b><\/p>\n<p>\n        <b>About UBRELVY<sup>\u00ae<\/sup> (ubrogepant)<\/b><br \/>\n        <br \/>UBRELVY<sup>\u00ae<\/sup> (ubrogepant) is an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the acute treatment of migraine with or without aura in adults that is an option for a wide range of patients who experience migraine attacks. UBRELVY<sup>\u00ae<\/sup> is the first pill of its kind to directly block CGRP, a protein released during a migraine attack, from binding to its receptors. <\/p>\n<p>\n        <b>IMPORTANT SAFETY INFORMATION<br \/>Who should not take UBRELVY<sup>\u00ae<\/sup> (ubrogepant)?<\/b><br \/>\n        <br \/>Do not take UBRELVY<sup>\u00ae<\/sup> if you are taking medicines known as strong CYP3A4 inhibitors, such as ketoconazole, clarithromycin, itraconazole.<br \/><b>What should I tell my healthcare provider before taking UBRELVY<sup>\u00ae<\/sup>?<\/b><br \/>Tell your healthcare provider about all your medical conditions, including if you:<\/p>\n<ul type=\"disc\">\n<li>Have liver problems <\/li>\n<li>Have kidney problems <\/li>\n<li>Are pregnant or plan to become pregnant <\/li>\n<li>Are breastfeeding or plan to breastfeed<\/li>\n<\/ul>\n<p>\n        <b>Tell your healthcare provider about all the medicines you take,<\/b>\u00a0including prescription and over-the-counter medicines, vitamins, and herbal supplements. Your healthcare provider can tell you if it is safe to take UBRELVY<sup>\u00ae<\/sup> with other medicines.<\/p>\n<p>\n        <b>What are the most common side effects of UBRELVY<sup>\u00ae<\/sup>?<\/b><br \/>\n        <br \/>The most common side effects are nausea (4%) and sleepiness (3%). These are not all of the possible side effects of UBRELVY<sup>\u00ae<\/sup>.<\/p>\n<p>\n        <b>What is UBRELVY<sup>\u00ae<\/sup> (ubrogepant)?<\/b><br \/>\n        <br \/>UBRELVY<sup>\u00ae<\/sup> is a prescription medicine used for the acute treatment of migraine attacks with or without aura in adults. UBRELVY<sup>\u00ae<\/sup> is not used to prevent migraine headaches.<br \/><b>Please see full\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=1660340889&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2937429-1%26h%3D1906669549%26u%3Dhttps%253A%252F%252Fmedia.allergan.com%252Fproducts%252FUbrelvy_pi.pdf%26a%3DPrescribing%2BInformation&amp;a=Prescribing+Information\" rel=\"nofollow noopener\">Prescribing Information<\/a>.<\/b><\/p>\n<p>\n        <b>About AbbVie Leadership in Migraine<\/b><br \/>\n        <br \/>AbbVie, a leader in the migraine space, markets BOTOX<sup>\u00ae<\/sup>\u00a0(onabotulinumtoxinA), the first FDA-approved, preventive treatment for adults with Chronic Migraine and UBRELVY<sup>\u00ae<\/sup>\u00a0(ubrogepant), the first FDA-approved oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant), which is indicated for the acute treatment of migraine with or without aura in adults.<\/p>\n<p>\n        <b>About AbbVie in Neuroscience<br \/><\/b>At AbbVie, our commitment to preserve the personhood of those living with neurological and psychiatric disorders is unwavering. Every challenge in this uncharted territory makes us more determined and drives us harder to discover and deliver solutions for patients, care partners and clinicians. AbbVie&#8217;s Neuroscience portfolio consists of approved therapies and a robust pipeline in neurological and psychiatric disorders, including Alzheimer&#8217;s disease,\u00a0bipolar I disorder, major depressive disorder, migraine, Parkinson&#8217;s disease,\u00a0spinal cord injuries, post-stroke spasticity, schizophrenia, stroke and others. <\/p>\n<p>We have a strong investment in neuroscience research, with our Foundational Neuroscience Center in\u00a0Cambridge, <span class=\"xn-location\">Massachusetts<\/span>, and our Neuroscience Discovery site in Ludwigshafen,\u00a0Germany, where our research and resilience in these challenging therapeutic areas is yielding a deeper understanding of the pathophysiology of neurological and psychiatric disorders, and identifying targets for potential disease-modifying therapeutics aimed at making a difference in people&#8217;s lives. <\/p>\n<p>\n        <b>About AbbVie<\/b><br \/>\n        <br \/>AbbVie&#8217;s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people&#8217;s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women&#8217;s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=1505306681&amp;u=http%3A%2F%2Fwww.abbvie.com%2F&amp;a=www.abbvie.com\" rel=\"nofollow noopener\">www.abbvie.com<\/a>. Follow <u>@AbbVie<\/u> on <u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=3272539235&amp;u=https%3A%2F%2Ftwitter.com%2Fabbvie&amp;a=Twitter\" rel=\"nofollow noopener\">Twitter<\/a><\/u>, <u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=1393058827&amp;u=https%3A%2F%2Fwww.facebook.com%2FAbbVieGlobal%2F&amp;a=Facebook\" rel=\"nofollow noopener\">Facebook<\/a><\/u>, <u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=254748205&amp;u=https%3A%2F%2Fwww.instagram.com%2Fabbvie%2F&amp;a=Instagram\" rel=\"nofollow noopener\">Instagram<\/a><\/u>, <u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=4028403652&amp;u=https%3A%2F%2Fwww.youtube.com%2Fuser%2FAbbVie&amp;a=YouTube%C2%A0\" rel=\"nofollow noopener\">YouTube<u>\u00a0<\/u><\/a><\/u>and\u00a0<u><a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3175442-1&amp;h=2043134329&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fabbvie%2F&amp;a=LinkedIn\" rel=\"nofollow noopener\">LinkedIn<\/a><\/u>.<\/p>\n<p>\n        <b>Forward-Looking Statements<\/b><br \/>\n        <br \/>\n        <i>Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;anticipate,&#8221; &#8220;project&#8221; and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie&#8217;s acquisition of Allergan plc (&#8220;Allergan&#8221;), failure to promptly and effectively integrate Allergan&#8217;s businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie&#8217;s operations is set forth in Item 1A, &#8220;Risk Factors,&#8221; of AbbVie&#8217;s <\/i><br \/>\n        <i>2020<\/i><br \/>\n        <i>\u00a0Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.<\/i>\n      <\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG89773&amp;sd=2021-05-26\" \/> View original content:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting-301299437.html\">http:\/\/www.prnewswire.com\/news-releases\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting-301299437.html<\/a><\/p>\n<p>SOURCE  AbbVie<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=CG89773&amp;Transmission_Id=202105260800PR_NEWS_USPR_____CG89773&amp;DateId=20210526\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8212; Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine are among several abstracts &#8212; Interim results on the real-world effectiveness of UBRELVY\u00ae (ubrogepant) for the acute treatment of migraine in combination with calcitonin gene-related peptide receptor (CGRP) monoclonal antibody (mAb) preventives, BOTOX\u00ae (onabotulinumtoxinA), or both from the Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study &#8212; Real-world data on the role of BOTOX\u00ae (onabotulinumtoxinA) in combination with CGRP mAbs for Chronic Migraine prevention PR Newswire NORTH CHICAGO, Ill., May 26, 2021 \/PRNewswire\/ &#8212; AbbVie (NYSE: ABBV) today announced data from its migraine portfolio will be presented at the 2021 American Headache Society (AHS) Annual Scientific Meeting, to be held virtually &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-498830","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8212; Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine are among several abstracts &#8212; Interim results on the real-world effectiveness of UBRELVY\u00ae (ubrogepant) for the acute treatment of migraine in combination with calcitonin gene-related peptide receptor (CGRP) monoclonal antibody (mAb) preventives, BOTOX\u00ae (onabotulinumtoxinA), or both from the Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study &#8212; Real-world data on the role of BOTOX\u00ae (onabotulinumtoxinA) in combination with CGRP mAbs for Chronic Migraine prevention PR Newswire NORTH CHICAGO, Ill., May 26, 2021 \/PRNewswire\/ &#8212; AbbVie (NYSE: ABBV) today announced data from its migraine portfolio will be presented at the 2021 American Headache Society (AHS) Annual Scientific Meeting, to be held virtually &hellip; Continue reading &quot;AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-26T12:06:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG89773&amp;sd=2021-05-26\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"16 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting\",\"datePublished\":\"2021-05-26T12:06:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\\\/\"},\"wordCount\":3157,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG89773&amp;sd=2021-05-26\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\\\/\",\"name\":\"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG89773&amp;sd=2021-05-26\",\"datePublished\":\"2021-05-26T12:06:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG89773&amp;sd=2021-05-26\",\"contentUrl\":\"https:\\\/\\\/c212.net\\\/c\\\/img\\\/favicon.png?sn=CG89773&amp;sd=2021-05-26\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/","og_locale":"en_US","og_type":"article","og_title":"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting - Market Newsdesk","og_description":"&#8212; Phase 3 ADVANCE trial results on the safety and efficacy of atogepant in the preventive treatment of migraine are among several abstracts &#8212; Interim results on the real-world effectiveness of UBRELVY\u00ae (ubrogepant) for the acute treatment of migraine in combination with calcitonin gene-related peptide receptor (CGRP) monoclonal antibody (mAb) preventives, BOTOX\u00ae (onabotulinumtoxinA), or both from the Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study &#8212; Real-world data on the role of BOTOX\u00ae (onabotulinumtoxinA) in combination with CGRP mAbs for Chronic Migraine prevention PR Newswire NORTH CHICAGO, Ill., May 26, 2021 \/PRNewswire\/ &#8212; AbbVie (NYSE: ABBV) today announced data from its migraine portfolio will be presented at the 2021 American Headache Society (AHS) Annual Scientific Meeting, to be held virtually &hellip; Continue reading \"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2021-05-26T12:06:06+00:00","og_image":[{"url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG89773&amp;sd=2021-05-26","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"16 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting","datePublished":"2021-05-26T12:06:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/"},"wordCount":3157,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG89773&amp;sd=2021-05-26","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/","name":"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG89773&amp;sd=2021-05-26","datePublished":"2021-05-26T12:06:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/#primaryimage","url":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG89773&amp;sd=2021-05-26","contentUrl":"https:\/\/c212.net\/c\/img\/favicon.png?sn=CG89773&amp;sd=2021-05-26"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/abbvie-to-present-data-from-its-leading-migraine-portfolio-at-the-2021-american-headache-society-ahs-annual-scientific-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"AbbVie to Present Data from its Leading Migraine Portfolio at the 2021 American Headache Society (AHS) Annual Scientific Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/498830","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=498830"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/498830\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=498830"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=498830"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=498830"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}